Organogenesis Holdings Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 79/100
What the filing says
Organogenesis reported Q2 2026 net revenue of $42.8M, down 58% YoY from $100.8M, with Advanced Wound Care collapsing 61% to $36.1M and Surgical Sports Medicine declining 18% to $6.7M. Net loss widened dramatically to $96.3M (or –$0.77/share) from –$9.4M (–$0.10/share) YoY; adjusted EBITDA loss reached –$34.4M vs –$3.6M. Management cut full-year 2026 guidance to $179–$215M (62–68% decline vs 2025's $564.2M), citing slower-than-expected market recovery. Cash fell to $46.8M from $94.3M at year-end 2025; the company took $5.1M restructuring charges and terminated R&D programs totaling $5.6M.
Why this rating
58% revenue collapse + 10x loss swing is severe; guidance cut validates deterioration. Material to ~$300M market cap but not existential (still has cash, no debt).
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.